Graviton BioScience Wins FDA Fast Track for GV101 Therapy
New York, USA, November 3, 2026 Graviton BioScience Corporation has announced that the U.S. Food and Drug Administration (FDA)...
rare disease research
Advertisement
Lundbeck Completes Enrollment in Phase III Dravet Trial
Copenhagen, Denmark, September 15, 2026 H. Lundbeck A/S has announced that the last patient has been randomized in DEEp...
BioMarin Partners n-Lorem on First ReNU Syndrome Therapy
SAN RAFAEL, Calif. & SAN DIEGO, July 27, 2026 BioMarin Pharmaceutical Inc. and the n-Lorem Foundation have announced a...
Pretzel Therapeutics PX578 Shows Promise for POLG Disease
WALTHAM, Mass. — March 11, 2026 Pretzel Therapeutics announced new preclinical data for its lead therapeutic candidate PX578 during...
Vectory Doses First Patient in Phase 1/2 ALS Trial
Amsterdam, Netherlands | February 9 2026 — Vectory Therapeutics has announced that the first participant has been dosed in...
Advertisement
